Eagle Health Investments LP Takes Position in Kymera Therapeutics, Inc. $KYMR
Eagle Health Investments LP initiated a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during Q4, acquiring 136,300 shares valued at approximately $10.6 million. This investment represents 2.3% of Eagle Health's portfolio. Kymera Therapeutics recently surpassed quarterly earnings expectations, reporting an EPS loss of $0.71 on revenues of $34.37 million, significantly outperforming estimates, while Wall Street analysts maintain a bullish outlook with an average price target of $118.10 despite some recent insider selling.
CCORF Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $106
CCORF has reiterated its Buy rating for Kymera Therapeutics (KYMR.US) and maintained its target price of $106. This indicates continued confidence in the company's stock performance and future outlook from the analyst firm.
Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end
Kymera Therapeutics expects to release Phase 1 data for its KT-579 program in the second half of 2026. Simultaneously, the company is aiming to complete enrollment for the BROADEN2 study of KT-621 by the end of the current year. These updates were provided during Kymera's first-quarter 2024 earnings call.
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Kymera Therapeutics announced presentations at the Society for Investigative Dermatology (SID) and American Thoracic Society (ATS) congresses highlighting positive results from its KT-621 BroADen Phase 1b trial. KT-621 is a first-in-class, oral STAT6 degrader for Type 2 inflammatory diseases like atopic dermatitis and asthma. The data showed deep STAT6 degradation in blood and skin, reductions in inflammatory biomarkers, and promising clinical activity with a favorable safety profile, supporting its potential as a novel oral systemic therapy.
Wellington group holds 3.89M shares in Kymera (KYMR) — 4.76% stake
Wellington group entities have reported a shared beneficial ownership of 3,889,687 shares, representing a 4.76% stake in Kymera Therapeutics, Inc. (KYMR), as of March 31, 2026. This information comes from a Schedule 13G/A amendment filing, which indicates that the shares are owned by clients of Wellington investment advisers. The filing highlights shared voting power of 3,543,178 shares and shared dispositive power of 3,889,687 shares.
Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses
Kymera Therapeutics is set to present information on KT-621, an oral Stat6 degrader, at two upcoming medical congresses: the Society for Investigative Dermatology and the American Thoracic Society. KT-621 is described as a first-in-class treatment, currently in Phase I clinical trials for healthy volunteers, and has recently received FDA Fast Track designation for moderate to severe asthma. The company focuses on developing small molecule therapeutics using its targeted protein degradation platform for immunology programs.
Kymera presents KT-621 atopic dermatitis trial data at conferences
Kymera Therapeutics presented positive Phase 1b trial data for KT-621, an oral STAT6 degrader for atopic dermatitis, at two medical conferences. The data showed STAT6 degradation in blood and skin, reductions in inflammatory biomarkers, and early activity evidence in asthma patients, leading to a 181% stock return over the past year. The company is now advancing KT-621 into parallel Phase 2b trials for atopic dermatitis and asthma, with data anticipated in mid-to-late 2027.
KT-579’s Biologics-Like Oral Data Might Change The Case For Investing In Kymera Therapeutics (KYMR)
Kymera Therapeutics recently reported preclinical data for KT-579, an oral IRF5 degrader, showing it achieved disease-modifying activity in an inflammatory bowel disease model comparable to or exceeding benchmark therapies. This suggests KT-579 could offer biologics-like immune pathway control in a pill, potentially broadening treatment options for autoimmune diseases. This positive preclinical data, along with the Fast Track designation for KT-621, reinforces Kymera's platform approach to oral immunology drugs, though investors should still consider the risks of high R&D spend and reliance on future clinical trial success.
Kymera Therapeutics stock (US50153V1061): Featured in psoriasis pipeline report
Kymera Therapeutics is featured in a 2026 global psoriasis competitive landscape analysis as a Tier 3 emerging player, developing IRAK4/STAT6 degraders. The company's pipeline includes candidates like KT-474 and KT-621, with revenue primarily from collaborations with partners like Sanofi and GSK. This recognition comes as Janssen's Icotrokinra recently received FDA approval, highlighting the evolving landscape of psoriasis treatments and the potential for oral options like Kymera's degraders.
BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation
BTIG has reiterated its Buy recommendation for Kymera Therapeutics (KYMR). This indicates a continued positive outlook from the firm regarding the company's stock and prospects.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts
Kymera Therapeutics (NASDAQ:KYMR) has received a consensus "Moderate Buy" rating from 23 analysts, with an average 12-month price target of $118.10. The company recently reported better-than-expected quarterly results, with a narrower loss of $0.71 per share against an estimated $0.89 loss, and revenue of $34.37 million, significantly exceeding forecasts and up 55.5% year-over-year. While some insider selling has occurred, institutional investors have generally increased their positions in the stock.
Kymera Therapeutics stock (US50153V1061): Director sells $261K in shares amid strong Q1 revenue
Kymera Therapeutics director Elena Ridloff sold shares valued at $261,000, following previous sales exceeding $1 million. This insider activity accompanies the company's strong Q1 revenue of $34.36 million, significantly surpassing expectations due to its collaboration with Gilead Sciences. The biotech firm, listed on Nasdaq, focuses on protein degradation technology for immunology and oncology.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Purcell & Lefkowitz LLP has launched a shareholder investigation into Kymera Therapeutics, Inc. (NASDAQ: KYMR) to determine if its directors breached their fiduciary duties regarding recent corporate actions. Shareholders seeking more information about their rights and options are encouraged to contact the law firm. Purcell & Lefkowitz LLP specializes in representing shareholders affected by securities fraud and corporate misconduct.
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock
Kymera Therapeutics director Elena Ridloff sold 3,000 shares of company stock for $261,000, after exercising stock options at a lower price. This transaction was conducted under a Rule 10b5-1 trading plan. Despite the sale, Ridloff retains 13,000 derivative shares in stock options, and the company recently reported strong Q1 2026 earnings, though InvestingPro analysis suggests the stock is currently overvalued.
Kymera Therapeutics director Elena Ridloff sells $261,000 in stock By Investing.com
Elena Ridloff, a director at Kymera Therapeutics (NASDAQ:KYMR), sold common stock worth $261,000 on May 11, 2026, after exercising fully vested stock options. Following these transactions executed under a Rule 10b5-1 trading plan, Ridloff holds no direct common stock but retains 13,000 derivative shares in stock options. This sale occurred while the stock has seen a 186% gain over the past year, though InvestingPro analysis suggests it is currently overvalued.
KYMR (KYMR) Form 144: 3,000-share sale; prior 10b5-1 sales disclosed
Kymera Therapeutics (KYMR) filed a Form 144, indicating a proposed sale of 3,000 common shares as a result of stock option exercises on May 11, 2026. The filing also disclosed earlier 10b5-1 sales by Elena Ridloff, totaling 4,600 shares for $392,921.88 on April 1, 2026, and 7,400 shares for $631,738.74 on March 31, 2026. This Form 144 serves as a notification and does not directly execute the transaction.
Kymera (KYMR) director Ridloff exercises options, sells 3,000 shares under 10b5-1 plan
Kymera Therapeutics director Elena Ridloff exercised stock options for 3,000 shares at $31.20 each and simultaneously sold all 3,000 shares in an open-market transaction at $87.00 per share. These transactions, which occurred on May 11, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan dated December 11, 2025. Following these trades, Ridloff holds no direct common stock but retains 13,000 exercisable stock options expiring in 2034.
Kymera Therapeutics stock (US50153V1061): Up after Q1 beat and new IBD data for KT-579 degrader cand
Kymera Therapeutics shares rose following a better-than-expected Q1 2026 earnings report and new preclinical data for its oral IRF5 degrader, KT-579, in inflammatory bowel disease models. The company's revenue beat, largely driven by collaboration and licensing income, and the promising IBD data have boosted sentiment despite ongoing net losses. Kymera's business model relies on its targeted protein degradation technology and partnerships for revenue, with significant future potential tied to the clinical success of its pipeline candidates like KT-579 and KT-621.
State of New Jersey Common Pension Fund D Makes New $2.61 Million Investment in Kymera Therapeutics, Inc. $KYMR
The State of New Jersey Common Pension Fund D has made a new $2.61 million investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR), purchasing 33,538 shares in the fourth quarter. This comes amidst significant insider selling totaling over $32 million in the last quarter, though company insiders still hold 16.01% of the stock. Kymera Therapeutics recently reported stronger-than-expected quarterly earnings and revenue, leading analysts to maintain a "Moderate Buy" rating with an average target price of $118.10.
Kymera Therapeutics (KYMR) Is Up 5.8% After New KT-579 IBD Data Highlights Oral Degrader Potential
Kymera Therapeutics (KYMR) saw its stock rise 5.8% following the release of new preclinical data for its oral IRF5 degrader, KT-579, showing disease-modifying activity in inflammatory bowel disease (IBD) models. This data suggests KT-579 could potentially impact multiple disease pathways in IBD, broadening Kymera's immunology franchise. The company also reported Q1 2026 results with a net loss of US$69.23 million, as investors await further clinical trial results for KT-579 and KT-621.
Kymera Therapeutics (KYMR) Is Up 5.8% After New KT-579 IBD Data Highlights Oral Degrader Potential
Kymera Therapeutics (KYMR) saw its stock rise by 5.8% following the release of new preclinical data for its oral IRF5 degrader, KT-579, showing disease-modifying activity in inflammatory bowel disease (IBD) models. This data suggests KT-579 could broaden Kymera's immunology franchise by potentially influencing multiple disease pathways with a single oral degrader. Despite promising scientific advancements, the company continues to face quarterly net losses, emphasizing ongoing funding and execution risks, with investor focus also on upcoming Phase 1 safety and KT-621 mid-stage readouts.
FMR LLC holds 14.3% of Kymera Therapeutics (NASDAQ: KYMR) in 13G/A
FMR LLC has filed an amended Schedule 13G/A, disclosing a 14.3% beneficial ownership stake in Kymera Therapeutics (NASDAQ: KYMR). This amounts to 11,681,450.45 shares, with FMR LLC exercising sole voting power over 11,666,707 shares and sole dispositive power over all 11,681,450.45 shares. The filing indicates a passive investment intent, as is typical for Schedule 13G/A amendments.
Canaccord Genuity initiates coverage of Kymera Therapeutics (KYMR) with buy recommendation
Canaccord Genuity has initiated coverage on Kymera Therapeutics (KYMR) with a buy recommendation. The firm now officially covers the biotechnology company, suggesting a positive outlook for its stock.
Vanguard Group Inc. Buys 845,922 Shares of Kymera Therapeutics, Inc. $KYMR
Vanguard Group Inc. increased its stake in Kymera Therapeutics, Inc. by 15.6% during the fourth quarter, acquiring an additional 845,922 shares and bringing its total holdings to 6,267,644 shares valued at $487,685,000. Other institutional investors also adjusted their positions in KYMR, while analysts have maintained a "Moderate Buy" consensus rating with an average price target of $118.10. The company recently reported strong Q1 earnings, beating analyst estimates, and has a market capitalization of $6.80 billion.
UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR
UBS Group AG increased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 13.6% in the fourth quarter, purchasing an additional 88,314 shares and now owning 737,032 shares valued at approximately $57.35 million. Other institutional investors also adjusted their positions, while company insiders like Noah Goodman and Nello Mainolfi sold significant shares, primarily for tax obligations. Kymera Therapeutics recently reported Q1 earnings that beat analyst estimates, with positive preclinical data for KT‑579 and an overall "Moderate Buy" consensus rating from analysts, despite mixed sentiment regarding future growth forecasts.
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in May 2026. The company will present at the Bank of America 2026 Healthcare Conference and the RBC Capital Markets 2026 Global Healthcare Conference. Live webcasts and replays of these presentations will be available on Kymera's investor relations website.
Kymera lines up two May investor webcasts from Las Vegas and New York
Kymera Therapeutics (NASDAQ: KYMR) will participate in two investor conferences in May 2026, presenting fireside chats. The first is on May 12, 2026, at the Bank of America Healthcare Conference in Las Vegas, and the second is on May 19, 2026, at the RBC Capital Markets Global Healthcare Conference in New York. Live webcasts and archived replays will be accessible on the company's website.
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
Kymera Therapeutics announced new preclinical data for KT-579, an oral IRF5 degrader, demonstrating significant disease-modifying activity in inflammatory bowel disease (IBD) models. The findings presented at Digestive Disease Week show KT-579's potential as a novel oral approach for complex autoimmune diseases by modulating multiple inflammatory pathways. The Phase 1 healthy volunteer trial for KT-579 is ongoing, with data expected in the second half of 2026.
Oral bowel disease drug matched approved therapies in preclinical tests
Kymera Therapeutics presented encouraging preclinical data for its oral IRF5 degrader, KT-579, showing it effectively reduced disease activity and inflammatory cytokines in an IBD model. The company reported that KT-579's efficacy was comparable or superior to existing approved therapies, broadly normalizing inflammatory and fibrosis-associated pathways. A Phase 1 healthy volunteer trial is currently underway, with human data anticipated in the second half of 2026.
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at Digestive Disease Week, showing promising activity in an inflammatory bowel disease (IBD) model. The data indicate that KT-579 can broadly modulate pathogenic pathways in IBD, offering a novel oral approach for complex autoimmune diseases. A Phase 1 healthy volunteer trial for KT-579 is ongoing, with data expected in the second half of 2026.
Kymera Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell in Celebration of its 10-Year Anniversary
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oral small molecule degrader medicines, celebrated its 10-year anniversary by ringing the Nasdaq Stock Market Opening Bell. Nello Mainolfi, PhD, Founder, President, and CEO of Kymera, had the honor of ringing the bell at the Nasdaq MarketSite in Times Square.
Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary
Kymera Therapeutics, Inc. is ringing the Nasdaq Opening Bell to celebrate its 10-year anniversary. Nello Mainolfi, PhD, Founder, President, and CEO, will represent the clinical-stage biopharmaceutical company, which focuses on developing oral small molecule degrader medicines for immunological diseases. The event will take place at the Nasdaq MarketSite in Times Square on May 4, 2026.
Kymera Launches Parallel Phase 2b Trials for STAT6 Degrader KT-621
Kymera has initiated two parallel Phase 2b trials, BROADEN2 and BREADTH, for its oral STAT6 degrader KT-621. These trials will evaluate KT-621 in atopic dermatitis patients and eosinophilic asthma patients, respectively, with staggered readouts expected in mid- and late-2027. The drug's success in asthma, particularly its ability to improve FEV1 more significantly than existing biologics, will be a key differentiator.
Kymera Advances STAT6 Degrader KT-621 in Phase 2b Atopic Dermatitis, Asthma Trials
Kymera is progressing its oral STAT6 degrader, KT-621, into two Phase 2b trials for atopic dermatitis (BROADEN2) and asthma (BREADTH). The company aims to demonstrate that degrading STAT6, a transcription factor activated by IL-4/IL-13, can achieve deeper and broader suppression of Type 2 inflammation than existing injectable biologics. The success of KT-621 hinges on its ability to show superior clinical responses, particularly the EASI-75 response rate in atopic dermatitis compared to dupilumab, to validate its novel mechanism of action.
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR) and Teleflex (TFX)
This article provides an overview of recent analyst ratings for three healthcare companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR), and Teleflex (TFX). RBC Capital analysts maintained various ratings and price targets for these companies. Bicycle Therapeutics received a Moderate Buy consensus, Kymera Therapeutics a Strong Buy, and Teleflex a Moderate Buy consensus from the Street.
Kymera Therapeutics (NasdaqGM:KYMR) Stock Forecast & Analyst Predictions
Kymera Therapeutics (NasdaqGM:KYMR) is forecast to experience a decline in earnings at 6.5% per annum, while revenue is expected to grow at 23.7% annually. Analysts have recently adjusted price targets and boosted EPS estimates, reflecting mixed sentiment but overall constructive views on the company's STAT6 degrader programs and broader pipeline, with a blended analyst price target around $119. The company remains unprofitable but its revenue growth is expected to outperform the US market.
Kymera Therapeutics, Inc. (KYMR) reports Q1 loss, tops revenue estimates
Kymera Therapeutics, Inc. (KYMR) announced a narrower-than-expected loss for the first quarter, reporting a loss of 69 cents per share compared to analyst estimates of a 93 cent loss. The company also surpassed revenue expectations, bringing in $42.66 million against a forecast of $20.7 million. This positive financial performance was driven primarily by a collaboration revenue increase.
Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR
Jennison Associates LLC significantly reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 51.7% during the fourth quarter, selling over 531,000 shares. Despite this reduction, other institutional investors like Vanguard Group Inc. increased their holdings. The article also details recent analyst ratings, insider selling activity, and Kymera Therapeutics' financial performance, including its latest earnings report which beat analyst expectations for revenue and EPS.
Kymera’s KT-621 Advances in Phase 2b Atopic Dermatitis and Asthma Trials
Kymera's oral once-daily STAT6 degrader, KT-621, is currently undergoing two parallel Phase 2b trials for moderate-to-severe atopic dermatitis (BROADEN2) and eosinophilic asthma (BREADTH), with data expected in mid to late 2027. The drug has shown deep STAT6 degradation and clinical signals in earlier trials, and has received FDA Fast Track designation for both indications. Kymera also has KT-579, an IRF5 degrader for autoimmune diseases, in Phase 1 trials, with strong financial backing extending into 2029.
Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen
Wall Street Zen has upgraded Kymera Therapeutics (NASDAQ:KYMR) from a "sell" to a "hold" rating, contributing to a consensus "Moderate Buy" rating among analysts with an average price target of $118.70. The upgrade follows Kymera's strong quarterly performance, where it surpassed EPS and revenue expectations, reporting a 55.5% year-over-year revenue increase. However, the company has seen significant insider selling, with over 380,000 shares sold by insiders in the last 90 days.
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $119
Morgan Stanley has reiterated its Buy rating for Kymera Therapeutics (KYMR.US), maintaining a target price of $119. This indicates a continued positive outlook from the financial firm regarding the company's stock performance.
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics (KYMR) reported a narrower-than-expected loss of 71 cents per share in Q1 2026, beating the Zacks Consensus Estimate. Revenues surged 55.5% year-over-year to $34.37 million, significantly exceeding estimates, primarily due to collaboration with Gilead Sciences (GILD). The company's pipeline is advancing, with Gilead exercising its option to license KT-200 and KT-621 progressing in phase IIb trials for inflammatory diseases.
Kymera Therapeutics (NASDAQ:KYMR) Posts Earnings Results, Beats Expectations By $0.18 EPS
Kymera Therapeutics (NASDAQ:KYMR) exceeded Q1 earnings expectations, reporting a loss of ($0.71) EPS against a consensus of ($0.89), and revenue of $34.37 million, significantly higher than the $8.27 million estimate. The company highlighted strong progress in its pipeline, including advancing multiple drug candidates with partners Gilead and Sanofi, and maintaining a robust cash position of $1.55 billion, providing a runway into 2029. Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $118.70, despite recent insider stock sales.
Kymera Therapeutics Releases Q1 2026 Financial Results
Kymera Therapeutics (KYMR) reported Q1 2026 financial results, posting a narrower-than-expected loss of $0.71 per share, beating analyst estimates by 21.1%. The company's revenue increased by 55.4% year-over-year to $34.4 million, reflecting progress in clinical programs and collaborations. Kymera maintains a strong financial position with $1.55 billion in cash, cash equivalents, and investments.
Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative
Kymera Therapeutics reported deepening losses in Q1 2026, with a US$311 million net loss over the last twelve months despite revenue of US$39.2 million. While analysts forecast 45.3% annual revenue growth, profitability is not expected within the next three years due to high R&D spending and ongoing losses. The company's valuation and analyst price targets present a mixed picture, with some concerns about dilution and insider selling.
Press Release: Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics has released its financial results for the first quarter of 2026 and provided a business update. The release covers the company's financial performance during this period and outlines key developments in its operations and strategic initiatives. This information aims to inform stakeholders about the company's progress and financial health.
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported its first-quarter 2026 financial results, highlighting ongoing clinical trials for KT-621 in atopic dermatitis and asthma, and KT-579 in healthy volunteers. The company received a $45 million milestone payment from Gilead Sciences for the exclusive license of KT-200 and maintains a strong cash position of $1.55 billion, providing a runway into 2029. Kymera emphasized its commitment to advancing its pipeline of oral small molecule degrader medicines for immunological diseases and cancer.
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M
Kymera Therapeutics, Inc. (KYMR) reported Q1 revenue of $34.4 million, significantly exceeding the FactSet estimate of $8.3 million. This positive revenue surprise comes alongside other recent news, including the company winning FDA Fast Track designation for its oral asthma drug KT-621 and receiving a $45 million milestone payment from Gilead Sciences for KT-200. The company's shares experienced a fall after its Q1 loss narrowed, with collaboration revenue rising.
Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone
Kymera Therapeutics reported its Q1 2026 financial results, showing increased collaboration revenue of $34.4 million, driven by its partnership with Gilead Sciences, and a net loss of $69.2 million. The company boasts a strong cash position of $1.55 billion, projected to fund operations into 2029, and highlighted significant pipeline progress including FDA Fast Track designation for KT-621 and a $45 million milestone payment from Gilead for KT-200. Kymera continues to advance its clinical programs, KT-621 and KT-579, with several data readouts expected in 2027 and the second half of 2026, respectively.
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported Q1 2026 results, highlighting a strong cash position of $1.55 billion extending into 2029 and a $45 million milestone payment from Gilead for KT-200 licensing. The company is advancing KT-621 in Phase 2b trials for atopic dermatitis and asthma, with data expected by mid to late 2027, and KT-579 in a Phase 1 trial with data anticipated in 2H 2026.
